HomeCompareIUGNF vs PEP

IUGNF vs PEP: Dividend Comparison 2026

IUGNF yields 1788.91% · PEP yields 3.66%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IUGNF wins by $3531675981.86M in total portfolio value
10 years
IUGNF
IUGNF
● Live price
1788.91%
Share price
$0.11
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3531675982.01M
Annual income
$3,181,793,952,650,469.00
Full IUGNF calculator →
PEP
PepsiCo Inc.
● Live price
3.66%
Share price
$155.29
Annual div
$5.69
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$144.7K
Annual income
$63,430.49
Full PEP calculator →

Portfolio growth — IUGNF vs PEP

📍 IUGNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIUGNFPEP
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IUGNF + PEP cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IUGNF pays
PEP pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IUGNF
Annual income on $10K today (after 15% tax)
$152,057.25/yr
After 10yr DRIP, annual income (after tax)
$2,704,524,859,752,898.50/yr
PEP
Annual income on $10K today (after 15% tax)
$311.45/yr
After 10yr DRIP, annual income (after tax)
$53,915.92/yr
At 15% tax rate, IUGNF beats the other by $2,704,524,859,698,982.50/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IUGNF + PEP for your $10,000?

IUGNF: 50%PEP: 50%
100% PEP50/50100% IUGNF
Portfolio after 10yr
$1765837991.07M
Annual income
$1,590,896,976,356,949.80/yr
Blended yield
90.09%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PEP right now

IUGNF
No analyst data
Altman Z
-15.4
Piotroski
1/9
PEP
Analyst Ratings
1
Strong
15
Buy
28
Hold
1
Sell
Consensus: Hold
Price Target
$172.43
+11.0% upside vs current
Range: $156.00 — $191.00
Altman Z
3.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IUGNF buys
0
PEP buys
0
No recent congressional trades found for IUGNF or PEP in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIUGNFPEP
Forward yield1788.91%3.66%
Annual dividend / share$2.00$5.69
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$3531675982.01M$144.7K
Annual income after 10y$3,181,793,952,650,469.00$63,430.49
Total dividends collected$3506616114.25M$125.7K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: IUGNF vs PEP ($10,000, DRIP)

YearIUGNF PortfolioIUGNF Income/yrPEP PortfolioPEP Income/yrGap
1← crossover$189,591$178,890.88$10,854$514.44+$178.7KIUGNF
2$3,372,589$3,169,726.93$11,982$758.21+$3.36MIUGNF
3$56,305,450$52,696,779.78$13,526$1,136.44+$56.29MIUGNF
4$882,465,426$822,218,594.62$15,727$1,741.93+$882.45MIUGNF
5$12,987,684,313$12,043,446,306.47$19,012$2,750.28+$12987.67MIUGNF
6$179,550,479,073$165,653,656,858.63$24,173$4,514.44+$179550.45MIUGNF
7$2,332,406,409,977$2,140,287,397,368.80$32,789$7,793.80+$2332406.38MIUGNF
8$28,479,672,886,997$25,983,998,028,321.59$48,258$14,354.51+$28479672.84MIUGNF
9$326,992,550,798,860$296,519,300,809,773.56$78,586$28,686.63+$326992550.72MIUGNF
10$3,531,675,982,005,250$3,181,793,952,650,469.00$144,688$63,430.49+$3531675981.86MIUGNF

IUGNF vs PEP: Complete Analysis 2026

IUGNFStock

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.

Full IUGNF Calculator →

PEPConsumer Staples

PepsiCo, Inc. manufactures, markets, distributes, and sells various beverages and convenient foods worldwide. The company operates through seven segments: Frito-Lay North America; Quaker Foods North America; PepsiCo Beverages North America; Latin America; Europe; Africa, Middle East and South Asia; and Asia Pacific, Australia and New Zealand and China Region. It provides dips, cheese-flavored snacks, and spreads, as well as corn, potato, and tortilla chips; cereals, rice, pasta, mixes and syrups, granola bars, grits, oatmeal, rice cakes, simply granola, and side dishes; beverage concentrates, fountain syrups, and finished goods; ready-to-drink tea, coffee, and juices; dairy products; and sparkling water makers and related products. It serves wholesale and other distributors, foodservice customers, grocery stores, drug stores, convenience stores, discount/dollar stores, mass merchandisers, membership stores, hard discounters, e-commerce retailers and authorized independent bottlers, and others through a network of direct-store-delivery, customer warehouse, and distributor networks, as well as directly to consumers through e-commerce platforms and retailers. The company was founded in 1898 and is headquartered in Purchase, New York.

Full PEP Calculator →
📬

Get this IUGNF vs PEP comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IUGNF vs SCHDIUGNF vs JEPIIUGNF vs OIUGNF vs KOIUGNF vs MAINIUGNF vs MOIUGNF vs PMIUGNF vs GIS

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.